PTCT — PTC Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$70.93
+$0.37 (+0.52%)
PTC Therapeutics Inc (PTCT) is a biotechnology company listed on NASDAQ. It is led by Matthew B. Klein F.A.C.S., M.D., M.S., based in 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059, with about 991 employees. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Latest reported PTCT revenue for 2025-09-30 was $211.0M. Net income was $15.9M. Revenue was up 18.0% from 2025-06-30 to 2025-09-30. PTCT currently screens at market cap $6.51B.
Use this PTCT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PTCT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PTCT SEC filings page. Lician reads the product cache first so this HTML stays unique to PTC Therapeutics Inc even when a live quote feed is slow.
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
PTCT Key Statistics
Market Cap
$6.51B
Volume
160,211
Previous Close
$73.47
Day Range
$71.81 – $73.53
P/B Ratio
1743.27
EPS
-$4.73
Revenue
$806.78M
Net Income
-$363.30M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-14.0%
Profit Margin
-45.0%
Employees
991
PTCT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $806.78M | $937.82M | $698.80M | $538.59M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$363.30M | -$626.60M | -$559.02M | -$523.90M |
| EPS (Diluted) | -$4.73 | -$8.37 | -$7.79 | -$7.43 |
Total Assets
$1.71B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$779.71M
Operating Cash Flow
-$107.69M
Free Cash Flow
$0.00
PTC Therapeutics Inc Company Information
- CEO & Director
- Matthew B. Klein F.A.C.S., M.D., M.S.
- Headquarters
- 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059
- Website
- www.ptcbio.com
- Phone
- 908 222 7000
- IPO / Founded
- 2013-06-20
- Sector
- Healthcare
- Industry
- Biotechnology